Efficacy of Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy in Patients With Viral Suppression. Randomized, Open-label 96 Weeks Non-inferiority Trial.

Trial Profile

Efficacy of Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy in Patients With Viral Suppression. Randomized, Open-label 96 Weeks Non-inferiority Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs Atazanavir/ritonavir (Primary) ; Lamivudine; Nucleoside reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms SALT
  • Most Recent Events

    • 13 Sep 2016 Non-inferiority, 96 weeks follow-up analysis (n=286) published in the Journal of Antimicrobial Chemotherapy.
    • 25 Feb 2016 Results of sub-study of 96 weeks (n=92) presented at the 23rd Conference on Retroviruses and Opportunistic Infections
    • 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top